Bavencio misses in Phase III for NSCLC

Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) said Bavencio avelumab missed the primary endpoint in the Phase III JAVELIN Lung 200 trial to treat locally advanced, unresectable, recurrent or metastatic non-small cell lung cancer (NSCLC)

Read the full 354 word article

User Sign In